SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF
THE SECURITIES EXCHANGE ACT OF 1934

Date of Report (Date of earliest event reported) April 18, 2005

ICU MEDICAL, INC.

(Exact name of registrant as specified in its charter)

DELAWARE 0-19974 33-0022692
----(State or other jurisdiction (Commission File Number) (I.R.S. Employer of incorporation) Identification No.)

951 Calle Amanecer, San Clemente, California 92673

(Address of principal executive offices) (Zip Code)

(949) 366-2183 -----

Registrant's telephone number, including area code

N/A

(Former name or former address, if changed since last report)

INFORMATION TO BE INCLUDED IN THE REPORT

Item 8.01 Other Events

See attached press release.

Item 9.01 Financial Statements and Exhibits

(c) Exhibits

99.1 Press release, dated April 18, 2005 announcing ICU Medical, Inc.'s first quarter earnings.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this Report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: April 18, 2005

/s/ Francis J. O'Brien

Francis J. O'Brien Secretary, Treasurer and Chief Financial Officer ICU MEDICAL, INC. REPORTS FIRST QUARTER 2005 RESULTS

APRIL 18, 2005, SAN CLEMENTE, CALIFORNIA --ICU Medical, Inc., (NASDAQ/NMS:ICUI), a leading low cost manufacturer of safe medical connectors and custom intravenous systems, today announced results for the first quarter ended March 31, 2005.

First quarter revenue was \$27.1 million, as compared to \$22.2 million in the same period last year. Net income for the first quarter was \$4.4 million, or \$0.30 per diluted share, as compared to \$4.1 million, or \$0.28 per diluted share in the first quarter of 2004.

Commenting on the quarter, Frank O'Brien, ICU Medical's Chief Financial Officer, said, "The first quarter of 2005 is the best quarter we have had in a year and is a clear sign that the effect of Hospira's inventory reduction in 2004 is behind us. First quarter revenue and earnings exceeded our expectations and we now expect our annual results, exclusive of the Salt Lake City transaction, to be somewhat better than earlier expectations. Sales of our flagship CLAVE product both to Hospira and our other sales channels were all up significantly.

Mr. O'Brien continued, "On February 28, we announced a new manufacturing, commercialization and development agreement for Hospira's critical care line and our agreement to purchase Hospira's Salt Lake City manufacturing facility, related capital equipment and certain inventory for approximately \$35 million. We now expect to close the transaction on May 1, 2005. We will produce the products currently manufactured at the plant and Hospira will maintain commercial responsibility. We continue to see this as an excellent opportunity, which we expect will add approximately \$50 million to our revenues in 2005, with a small amount of profit in 2005 and increasing amounts thereafter."

ICU Medical's balance sheet remains strong, with cash and investments totaling \$96.1 million and no long-term debt at March 31, 2005. Operating cash flow was \$7.9 million for the first quarter. Capital expenditures were \$1.2 million in the quarter.

The foregoing statement concerning Management's expectation with respect to future results is a forward looking statement based upon the best information currently available to Management and assumptions Management believes are reasonable, but Management does not intend the statement to be a representation as to future results. Future results are subject to risks and uncertainties, including the risk factors described in the Company's filings with the Securities and Exchange Commission, which include those in the Form 10-K dated March 13, 2005. Actual results in the future may differ materially from Management's current expectations.

The Company will be conducting a conference call concerning its first quarter ended March 31, 2005 results at 1:30 p.m. PDT (4:30 p.m. EDT) on Monday, April 18, 2005, which can be accessed at 888-396-2384, passcode 75663589 or by replay at 888-286-8010, passcode I.D. 28448132. The conference call will be simultaneously available by webcast, which can be accessed by going to the Company's website at www.icumed.com, clicking on the Investors tab, clicking on the Webcast icon and following the prompts. The webcast will also be available by replay. Certain information provided as part of that call will be provided on the Company's website at www.icumed.com within 48 hours of this announcement.

CONTACT: Francis J. O'Brien
Chief Financial Officer
ICU Medical, Inc.
(949) 366-2183

John F. Mills Managing Director Integrated Corporate Relations (310) 395-2215

ICU Medical, Inc. Summary Consolidated Statements of Income (all dollar amounts in thousands except per share data) (unaudited)

	3,		onths Ended 3/31/2004	
Revenue Net Sales Other	\$	25,663 1,422		21 , 270 963
Total Revenue Cost of Sales		27,085 11,860		22,233 9,813
Gross Profit Selling, general and administrative expenses Research and development expenses		15,225 8,023 674		12,420 5,655 451
Total operating expenses	8,697			6,106
Income from operations Investment income		6,528 588		6,314 310
Income before income taxes and minority interest Minority interest Provision for income taxes		7,116 (72) 2,771		6,624 2,484
Net income	\$	4,417	\$	4,140
Net income per share - diluted		0.30		0.28
Weighted average number of common shares - diluted	14,762,038 =======		15,041,285	

ICU Medical, Inc. Summary Consolidated Balance Sheet Data (all dollar amounts in thousands except share data)

ASSETS

	(unaudited)		
	3/31/05	12/31/04	
CURRENT ASSETS:			
Cash and liquid investments	96,077	87,341	
Accounts receivable, net	11,793	8 , 922	
Inventories	7,373	8,429	
Prepaid and deferred taxes	6,463	7,732	
Other current assets	4,488	4,620	
Total current assets	126,194	117,044	
PROPERTY AND EQUIPMENT, NET	40,614	40,934	
OTHER ASSETS	6,496	6,790	
	\$173,304	\$164,768	
	=======	=======	

CURRENT LIABILITIES:	8,914	7,454
MINORITY INTEREST:	894	966
STOCKHOLDERS' EQUITY: 13,718,921 shares outstanding, net, at March 31, 2005	163,496 \$173,304 ======	156,348 \$164,768 ======

ICU Medical, Inc. Summary Consolidated Statements of Cash Flows (all dollar amounts in thousands) (unaudited)

	Three Months Ended			
			3/31/04	
CASH FLOWS FROM OPERATING ACTIVITIES: Net income Adjustments to reconcile net income to net cash provided by operating activities	\$	4,417	\$	4,140
Depreciation and amortization Net change in current assets and liabilities, and other		1,531 833		1,696 6,892
		6 , 781		12,728
Tax benefits from exercise of stock options		1,077		122
Net cash provided by operating activities		7,858		12,850
PURCHASES OF PROPERTY AND EQUIPMENT NET CHANGE IN LIQUID INVESTMENTS EMPLOYEE EQUITY PLANS OTHER				(1,410) (10,600) 543 628
NET INCREASE IN CASH AND CASH EQUIVALENTS	\$	836		2,011